NEW YORK and TOKYO, March 16, 2021 /PRNewswire/ — Perception Neuroscience (Perception), an atai Life Sciences (atai) company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd. (Otsuka), announce a collaboration and licensing agreement for the development and commercialization of Perception’s lead molecule, PCN-101 (R-ketamine) in Japan as…


Previous articleRed Light Holland Successfully Completes Sale and Import of iMicrodose Psychedelic Truffles into Canada Under a Health Canada Approved Psilocybin Import Permit
Next articleWorld Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor